Sugi Predict

Sugi Predict / Compounds / SCHEMBL15749495

SCHEMBL15749495

SCHEMBL15749495

CC(C)(C)OC(=O)N1CCC(=O)C(C)(F)C1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NR1H2 P55055 2/20 0.43
▸ USP2 O75604 1/20 0.41
▸ SMN1; SMN2 Q16637 1/20 0.41
▸ ESR2 Q92731 1/20 0.41
▸ DDB1 Q16531 3/20 0.40
▸ CRBN Q96SW2 3/20 0.40
▸ CYP11B2 P19099 1/20 0.38
▸ ADORA1 P30542 1/20 0.38
▸ PDK4 Q16654 1/20 0.38
▸ MAPT P10636 2/20 0.37
▸ USP30 Q70CQ3 1/20 0.37
▸ KDM4E B2RXH2 1/20 0.37
▸ THRB P10828 1/20 0.37
▸ ALDH1A1 P00352 1/20 0.37
▸ LMNA P02545 1/20 0.37
▸ RORC P51449 2/20 0.37
▸ CTSD P07339 1/20 0.37
▸ CTSE P14091 1/20 0.37
▸ BACE1 P56817 1/20 0.37
▸ HDAC2 Q92769 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30075744 1.00 NR1H2 (0.43) NR1H2USP2SMN1; SMN2ESR2DDB1
SCHEMBL518157 0.86 USP2 (0.42) NR1H2USP2SMN1; SMN2ESR2DDB1
Water SCHEMBL26621617 0.85 USP2 (0.41) NR1H2USP2SMN1; SMN2ESR2DDB1
SCHEMBL517374 0.84 NR1H2 (0.46) NR1H2USP2SMN1; SMN2ESR2DDB1
SCHEMBL20400529 0.82 GRM5 (0.40) NR1H2USP2SMN1; SMN2ESR2DDB1
Iodomethane SCHEMBL3387530 0.82 NR1H2 (0.44) NR1H2USP2SMN1; SMN2ESR2DDB1
SCHEMBL23578705 0.81 DDB1 (0.40) NR1H2USP2SMN1; SMN2ESR2DDB1
SCHEMBL23592779 0.81 DDB1 (0.40) NR1H2USP2SMN1; SMN2ESR2DDB1
SCHEMBL29201264 0.81 NR1H2 (0.40) NR1H2USP2SMN1; SMN2ESR2DDB1
SCHEMBL29207289 0.81 USP2 (0.41) NR1H2USP2SMN1; SMN2ESR2DDB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260116888-A1 CYCLIN-DEPENDENT KINASE INHIBITORS NOVARTIS AG (CH) 2026-04-30 — — US disclosed
US-12570655-B2 Cysteine covalent modifiers of AKT1 and uses thereof TERREMOTO BIOSCIENCES, INC. (US) 2026-03-10 — — US disclosed
EP-4695238-A1 CDK2 INHIBITORS Blueprint Medicines Corporation (US) 2026-02-18 — — EP disclosed
WO-2025081045-A9 CYSTEINE COVALENT MODIFIERS OF AKT1 AND USES THEREOF TERREMOTO BIOSCIENCES, INC. (US) 2025-12-26 — — WO disclosed
US-20250289801-A1 EGFR INHIBITORS BLUEPRINT MEDICINES CORPORATION 2025-09-18 — — US disclosed
US-20250289819-A1 CYSTEINE COVALENT MODIFIERS OF AKT1 AND USES THEREOF TERREMOTO BIOSCIENCES, INC. 2025-09-18 — — US disclosed
WO-2025081045-A1 CYSTEINE COVALENT MODIFIERS OF AKT1 AND USES THEREOF TERREMOTO BIOSCIENCES, INC. (US) 2025-04-17 — — WO disclosed
WO-2025059074-A1 BICYCLIC COMPOUNDS FOR RESTORING MUTANT P53 FUNCTION PMV PHARMACEUTICALS, INC. (US) 2025-03-20 — — WO disclosed
CN-115135642-B Inhibitors of EGFR mutant forms 缆图药品公司 2025-03-04 — — CN disclosed
US-12172983-B2 EGFR inhibitors BLUEPRINT MEDICINES CORPORATION (US) 2024-12-24 — — US disclosed
US-9890152-B2 Aminopyrimidine compounds as inhibitors of T790M containing EGFR mutants GENENTECH, INC. (US) 2018-02-13 — — US disclosed
US-9890152-B2 Aminopyrimidine compounds as inhibitors of T790M containing EGFR mutants GENENTECH, INC. (US) 2018-02-13 — — US disclosed
EP-2922851-B1 AMINOPYRIMIDINE COMPOUNDS AS INHIBITORS OF T790M CONTAINING EGFR MUTANTS GENENTECH INC (US) 2017-07-26 — — EP disclosed
EP-2922851-B1 AMINOPYRIMIDINE COMPOUNDS AS INHIBITORS OF T790M CONTAINING EGFR MUTANTS GENENTECH INC (US) 2017-07-26 — — EP disclosed
EP-3181564-A1 AMINOPYRIMIDINE COMPOUNDS AS INHIBITORS OF T790M CONTAINING EGFR MUTANTS Genentech, Inc. (US) 2017-06-21 — — EP disclosed
EP-3181564-A1 AMINOPYRIMIDINE COMPOUNDS AS INHIBITORS OF T790M CONTAINING EGFR MUTANTS Genentech, Inc. (US) 2017-06-21 — — EP disclosed
US-20160016948-A1 AMINOPYRIMIDINE COMPOUNDS AS INHIBITORS OF T790M CONTAINING EGFR MUTANTS GENENTECH, INC. (US) 2016-01-21 — — US disclosed
US-20160016948-A1 AMINOPYRIMIDINE COMPOUNDS AS INHIBITORS OF T790M CONTAINING EGFR MUTANTS GENENTECH, INC. (US) 2016-01-21 — — US disclosed
US-20160016948-A1 AMINOPYRIMIDINE COMPOUNDS AS INHIBITORS OF T790M CONTAINING EGFR MUTANTS GENENTECH, INC. (US) 2016-01-21 — — US disclosed
WO-2014081718-A1 AMINOPYRIMIDINE COMPOUNDS AS INHIBITORS OF T790M CONTAINING EGFR MUTANTS GENENTECH, INC. (US) 2014-05-30 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260116888-A1 CYCLIN-DEPENDENT KINASE INHIBITORS CDK4, CCNC, CDK6 NR1H2 1008/4885USP2 2411/4885SMN1; SMN2 3613/4885
US-12172983-B2 EGFR inhibitors EGFR, ERBB2, ERBB3 NR1H2 2807/4885USP2 2129/4885SMN1; SMN2 4618/4885
US-12570655-B2 Cysteine covalent modifiers of AKT1 and uses thereof AKT1, AKT2, AKT3 NR1H2 919/4885USP2 1960/4885SMN1; SMN2 4318/4885
US-20160016948-A1 AMINOPYRIMIDINE COMPOUNDS AS INHIBITORS OF T790M CONTAINING EGFR MUTANTS EGFR, ERBB2, ERBB3 NR1H2 3955/4885USP2 2330/4885SMN1; SMN2 4396/4885
US-20250289819-A1 CYSTEINE COVALENT MODIFIERS OF AKT1 AND USES THEREOF AKT1, AKT2, AKT3 NR1H2 3334/4885USP2 1319/4885SMN1; SMN2 4603/4885
US-20250289801-A1 EGFR INHIBITORS EGFR, ERBB2, ERBB3 NR1H2 2807/4885USP2 2129/4885SMN1; SMN2 4618/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.